Front page > Investment cases > Curasight

About Curasight

Curasight is a clinical phase II company with a technology built around the uPAR receptor, which is a biomarker expressed in most solid cancers. Curasight operates in the diagnosis and treatment of various cancers.

The company has developed a radiopharmaceutical platform that can be used both for diagnostics and for the treatment of cancer: uTRACE – which is used for cancer diagnostics has been used in more than 400 patients in a number of completed and ongoing investigator-initiated phase II clinical trials; and uTREAT – which have been successfully used in the treatment of cancer in translational studies.

Del indlægget på sociale media eller på email.